GOVXNasdaqPharmaceutical PreparationsFiscal year ends December 31
GeoVax Labs, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 27, 2026
$0.23−0.01 (-4.53%)
Close on Oct 19, 2026
- Market cap
- $1.04M
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
6.7%
0M of 7M shares
Institutional holders
17
5 new, 4 sold out
Net institutional buying
0M
In Q2 2026
Insider trades, 12 months
0 buys · 0 sales
Open-market trades only
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Waqas Khatri | 4,810,451 | 9.99% | 13G (passive) | Dec 31, 2025 |
| Armistice Capital, LLC | 291,155 | 9.99% | 13G (passive) amendment | Mar 31, 2026 |
| Mitchell P. Kopin | 2,849,344 | 9.99% | 13G (passive) amendment | Sep 30, 2025 |
| Intracoastal Capital LLC | 233,337 | 9.99% | 13G (passive) amendment | Mar 31, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of GOVX | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Jane Street Group, LLC | 315,275 | 4.28% | $400.40K | New | 0.00% |
| Hrt Financial LP | 126,704 | 1.72% | $160 | New | 0.00% |
| Geode Capital Management, LLC | 21,112 | 0.29% | $26.81K | −14,964 | 0.00% |
| Two Sigma Securities, LLC | 10,682 | 0.14% | $13.57K | New | 0.00% |
| Vanguard Fiduciary Trust Co | 5,068 | 0.07% | $6.44K | – | 0.00% |
| Tower Research Capital LLC (TRC) | 3,502 | 0.05% | $4.45K | −25 | 0.00% |
| Vanguard Capital Management LLC | 3,217 | 0.04% | $4.09K | – | 0.00% |
| SBI Securities Co., Ltd. | 2,588 | 0.04% | $3.29K | +2,204 | 0.00% |
| Morgan Stanley | 2,003 | 0.03% | $2.54K | +1,997 | 0.00% |
| Jones Financial Companies Lllp | 1,000 | 0.01% | $1.32K | New | 0.00% |
| UBS Group AG | 944 | 0.01% | $1.20K | −3,304 | 0.00% |
| BlackRock, Inc. | 842 | 0.01% | $1.07K | −251 | 0.00% |
| Citigroup Inc | 230 | 0.00% | $292 | New | 0.00% |
| Wells Fargo & Company/Mn | 30 | 0.00% | $38 | −1 | 0.00% |
| Danske Bank A/S | 3 | 0.00% | $4 | – | 0.00% |
| FMR LLC | 1 | 0.00% | $1 | – | 0.00% |
| Royal Bank of Canada | 1 | 0.00% | $0 | – | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 17 | 0M | 6.7% | 5 / 2 | 5 / 4 | 0M | 0M |
| Q1 2026 | 16 | 0M | 4.5% | 15 / 0 | 1 / 0 | 0M | 0M |
| Q4 2025 | 1 | 0M | 0.1% | 1 / 0 | 0 / 0 | 0M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of GOVX | Value | % of fund | As of |
|---|---|---|---|---|---|
| Fidelity Extended Market Index Fund | 22,245 | 0.30% | $45.82K | 0.00% | May 31, 2026 |
| Vanguard Extended Market Index Fund | 3,217 | 0.04% | $4.09K | 0.00% | Jun 30, 2026 |
| Fidelity Series Total Market Index Fund | 856 | 0.01% | $1.76K | 0.00% | May 31, 2026 |
| Fidelity Total Market Index Fund | 576 | 0.01% | $1.19K | 0.00% | May 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| David A. Dodd | President, CEO, Director | 36,661 | 0.50% | Jun 22, 2026 |
| Mark Reynolds | CFO | 14,013 | 0.19% | Jun 22, 2026 |
| Kelly T. McKee Jr. | Chief Medical Officer | 3,494 | 0.05% | Jun 22, 2026 |
| John W. Sharkey | VP, Business Development | 6,191 | 0.08% | Jun 22, 2026 |
| Mark J. Newman | Chief Scientific Officer | 3,000 | 0.04% | Jun 22, 2026 |
| John N. Spencer Jr | Director | 21,402 | 0.29% | Jun 22, 2026 |
| Jayne Morgan | Director | – | – | Jun 22, 2026 |
| Dean G. Kollintzas | Director | 11,987 | 0.16% | Jun 22, 2026 |
| Robert T. McNally | Director | 66,280 | 0.90% | Jun 22, 2026 |
| Randal D. Chase | Director | 36,613 | 0.50% | Jun 22, 2026 |
| Nicole Lemerond | Director | – | – | Jun 22, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| John N. Spencer Jr Director | Oct 17, 2025 | Buy | +10,000 | $0.55 | $5.50K | 21,402 |
| Kelly T. McKee Jr. Chief Medical Officer | Aug 7, 2025 | Buy | +1,107 | $0.67 | $742 | 3,494 |
| John N. Spencer Jr Director | Apr 10, 2025 | Buy | +10,000 | $0.98 | $9.80K | 11,402 |
| John W. Sharkey VP, Business Development | Apr 10, 2025 | Buy | +6,000 | $0.99 | $5.94K | 6,191 |
| David A. Dodd President, CEO, Director | Apr 1, 2025 | Buy | +10,000 | $1.08 | $10.80K | 36,661 |
| Mark Reynolds CFO | Mar 31, 2025 | Buy | +6,800 | $1.08 | $7.34K | 14,013 |
| David A. Dodd President, CEO, Director | Aug 9, 2024 | Buy | +8,000 | $1.95 | $15.60K | 26,661 |
| David A. Dodd President, CEO, Director | Feb 22, 2024 | Buy | +8,209 | $2.27 | $18.63K | 18,661 |
| David A. Dodd President, CEO, Director | Feb 21, 2024 | Buy | +520 | $2.15 | $1.12K | 10,452 |
| Mark Reynolds CFO | Feb 7, 2024 | Buy | +2,000 | $2.77 | $5.54K | 7,213 |
| Kelly T. McKee Jr. Chief Medical Officer | Dec 22, 2023 | Buy | +6,944 | $0.36 | $2.50K | 35,782 |
| Kelly T. McKee Jr. Chief Medical Officer | Sep 25, 2023 | Buy | +9,653 | $0.52 | $5.02K | 28,838 |
| David A. Dodd President, CEO, Director | Aug 25, 2023 | Buy | +35,087 | $0.57 | $20.00K | 148,957 |
| Mark Reynolds CFO | Aug 18, 2023 | Buy | +10,000 | $0.52 | $5.20K | 78,184 |
| David A. Dodd President, CEO, Director | Apr 24, 2023 | Buy | +32,000 | $0.64 | $20.48K | 113,870 |
| Mark Reynolds CFO | Apr 20, 2023 | Buy | +8,000 | $0.63 | $5.04K | 68,184 |
| Randal D. Chase Director | Sep 21, 2022 | Buy | +10,000 | $1.10 | $11.00K | 36,613 |
| John W. Sharkey VP, Business Development | Jul 1, 2022 | Buy | +1,000 | $0.82 | $820 | 2,860 |
| Kelly T. McKee Jr. Chief Medical Officer | Jun 27, 2022 | Buy | +4,464 | $1.12 | $5.00K | 19,185 |
| Randal D. Chase Director | Jun 21, 2022 | Buy | +10,000 | $1.21 | $12.10K | 26,613 |
| Kelly T. McKee Jr. Chief Medical Officer | May 5, 2022 | Buy | +9,722 | $0.72 | $7.00K | 14,721 |
| Kelly T. McKee Jr. Chief Medical Officer | May 4, 2022 | Buy | +4,999 | $0.71 | $3.55K | 4,999 |
| Randal D. Chase Director | Sep 29, 2020 | Buy | +16,613 | $5.00 | $83.07K | 16,613 |
| Mark Reynolds CFO | Sep 29, 2020 | Buy | +60,184 | $5.00 | $300.92K | 60,184 |
| David A. Dodd President, CEO, Director | Sep 29, 2020 | Buy | +81,870 | $5.00 | $409.35K | 81,870 |
| Dean G. Kollintzas Director | Sep 29, 2020 | Buy | +11,987 | $5.00 | $59.94K | 11,987 |
| Robert T. McNally Director | Sep 29, 2020 | Buy | +53,925 | $5.00 | $269.63K | 53,925 |
| John N. Spencer Jr Director | Sep 29, 2020 | Buy | +21,024 | $5.00 | $105.12K | 21,024 |
| Randal D. Chase Director | May 5, 2015 | Buy | +200 | $0.19 | $38 | 40,000 |
| Randal D. Chase Director | May 5, 2015 | Buy | +9,800 | $0.19 | $1.86K | 39,800 |
| Mark Reynolds CFO | Apr 23, 2015 | Buy | +10,000 | $0.18 | $1.80K | 66,000 |
| Mark Reynolds CFO | Apr 22, 2015 | Buy | +10,000 | $0.17 | $1.70K | 46,000 |
| Mark Reynolds CFO | Apr 22, 2015 | Buy | +10,000 | $0.17 | $1.70K | 56,000 |
| John N. Spencer Jr Director | Apr 20, 2015 | Buy | +18,000 | $0.17 | $3.06K | 46,625 |
| Randal D. Chase Director | Apr 20, 2015 | Buy | +30,000 | $0.17 | $5.10K | 30,000 |
| Harriet L. Robinson Chief Scientific Officer, Director | Jun 5, 2013 | Gift | −27,500 | – | – | 1,173,726 |
| Mark Reynolds CFO | Jan 31, 2012 | Buy | +15,000 | $0.67 | $10.05K | 36,000 |
| Steven S. Antebi Director | Jan 16, 2012 | Buy | +30,000 | $0.67 | $20.10K | 30,000 |
| John N. Spencer Jr Director | Dec 30, 2011 | Buy | +14,925 | $0.67 | $10.00K | 28,625 |
| Dean G. Kollintzas Director | Dec 30, 2011 | Buy | +14,925 | $0.67 | $10.00K | 14,925 |
| David A. Dodd Director | Dec 30, 2011 | Buy | +112,000 | $0.67 | $75.04K | 127,725 |
| Robert T. McNally President/CEO, Director | Dec 30, 2011 | Buy | +29,850 | $0.67 | $20.00K | 29,850 |
| Mark Reynolds CFO | Dec 30, 2011 | Buy | +15,000 | $0.67 | $10.05K | 21,000 |
| Harriet L. Robinson Chief Scientific Officer, Director | Dec 30, 2011 | Buy | +149,254 | $0.67 | $100.00K | 1,201,226 |
| Harriet L. Robinson Chief Scientific Officer, Director | Jun 22, 2011 | Gift | −7,422 | – | – | 1,051,972 |
| Harriet L. Robinson Chief Scientific Officer, Director | Jan 6, 2011 | Gift | −9,714 | – | – | 1,059,394 |
| Harriet L. Robinson Chief Scientific Officer, Director | Dec 20, 2010 | Gift | −33,333 | – | – | 1,069,108 |
| Robert T. McNally President & CEO, Director | Oct 15, 2010 | Gift | −8,300 | – | – | 0 |
| Mark Reynolds Chief Financial Officer | Jul 2, 2010 | Buy | +1,000 | $2.50 | $2.50K | 6,000 |
| Mark J. Newman VP, Research & Development | Jun 11, 2010 | Buy | +2,000 | $3.32 | $6.64K | 3,000 |
| Mark J. Newman VP, Research & Development | Jun 11, 2010 | Buy | +1,000 | $3.25 | $3.25K | 1,000 |
| Harriet L. Robinson Chief Scientific Officer, Director | Jun 10, 2010 | Buy | +2,100 | $3.35 | $7.04K | 1,102,441 |
| Harriet L. Robinson Chief Scientific Officer, Director | Jun 10, 2010 | Buy | +3,000 | $3.30 | $9.90K | 1,100,341 |
| Robert T. McNally President & CEO, Director | Jun 10, 2010 | Buy | +300 | $3.30 | $990 | 8,300 |
| Donald G. Hildebrand Director | Jun 9, 2010 | Buy | +1,000 | $3.29 | $3.29K | 19,000 |
| Robert T. McNally President & CEO, Director | Jun 9, 2010 | Buy | +100 | $3.30 | $330 | 7,100 |
| Robert T. McNally President & CEO, Director | Jun 9, 2010 | Buy | +900 | $3.32 | $2.99K | 8,000 |
| Mark Reynolds Chief Financial Officer | Jun 9, 2010 | Buy | +530 | $3.35 | $1.78K | 5,000 |
| Mark Reynolds Chief Financial Officer | Jun 9, 2010 | Buy | +570 | $3.34 | $1.90K | 4,470 |
| Mark Reynolds Chief Financial Officer | Jun 9, 2010 | Buy | +1,004 | $3.29 | $3.30K | 3,900 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.